Sage Therapeutics, Inc. (SAGE) analyst actions
SAGE analyst actions moved a median of 0.00% by the close. Rating and price-target actions on SAGE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SAGE overview →
11 measured SAGE analyst action events.
| Middle 50% of SAGE analyst action reactions | -0.64% to +1.33% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 11 |
Half of the 11 SAGE analyst action events with a measured close landed between -0.64% and +1.33%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | +0.06% | -0.22% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | +0.06% | +0.11% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | -0.43% | +1.20% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | +0.91% | -0.68% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | +2.05% | +3.36% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | +0.41% | -2.69% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | -0.35% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out | Press release | -0.27% | +1.47% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | -0.42% | -0.83% | |
| Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal | Press release | +0.41% | +2.34% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out | Press release | +0.33% | -0.60% |
More SAGE: earnings → · SEC filings → · SAGE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Natera, Inc. (NTRA) | 957 | +0.21% | 57% |
| Antares Pharma, Inc. (ATRS) | 951 | 0.00% | 43% |
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Intellia Therapeutics, Inc. (NTLA) | 948 | -0.24% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.